ASCO GI 2021 | KEYNOTE-177: translating results for patients and clinicians
Kai-Keen Shiu, FRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the importance of the results from KEYNOTE-177 (NCT02563002) for patients with bowel cancer, and their treating physicians, including the significance of determining whether tumors are microsatellite-instability high or mismatch repair deficient. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Disclosures
Honoraria from Bristol-Myers Squibb, Guardant Health, Innovent Biologics, Merck KGaA, Merck Sharp and Dohme, Roche
Consultant or Advisory Role from Merck Sharp and Dohme, Roche,
Research Funding from Bristol-Myers Squibb (Inst), Gilead Sciences (Inst), Merck KGaA (Inst), Merck Sharp and Dohme (Inst), Roche (Inst)
Travel, accommodations and expenses from Innovent Biologics, Merck KGaA, Roche
